Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics

Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics: a Multi-center Prospective Study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05722275

Enrollment

400

Registered

2023-02-10

Start date

2023-01-01

Completion date

2028-12-31

Last updated

2023-02-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Cancer, Peritoneal Metastases

Keywords

Artificial Intelligence, Classification, Gastric Cancer, Peritoneal Metastases, Computed Tomography, Radiomics

Brief summary

Peritoneal metastasis of gastric cancer is difficult to be detected in time, thus delaying treatment. Based on the conventional CT images of gastric cancer, this study plans to develop, improve and validate an intelligent analysis system based on radiomics. By extracting and combining the radiomics features related to peritoneal metastasis of gastric cancer, the intelligent analysis system could predict the risk of peritoneal metastasis, and provide personalized decision suggestions for the treatment of gastric cancer.

Detailed description

Interventions

DIAGNOSTIC_TESTPeritoneal metastasis status ascertainment

Each participant with gastric cancer will undergo enhanced CT examination for detection of peritoneal metastasis. Within two weeks of CT examination, the participant will undergo diagnostic laparoscopy to confirm the status of peritoneal metastasis.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* (1) diagnosed advanced gastric cancer (≥cT3) by endoscopy-biopsy pathology, combined with CT and/or endoscopic ultrasound; * (2) with both enhanced CT and laparoscopy; * (3) without typical peritoneal metastasis indications in CT (diffuse omental nodules or omental cake, large amount of ascites, obvious irregular thickening with high peritoneal enhancement); * (4) without other evidence of distant metastasis, and no stage IV features on CT.

Exclusion criteria

* (1) previous abdominal surgery; * (2) previous abdominal malignancies or inflammatory diseases; * (3) time intervals between CT and laparoscopy longer than 2 weeks; * (4) CT image artifacts that undermine peritoneal lesion assessment.

Design outcomes

Primary

Measure	Time frame	Description
The aera under the receiver operating characteristic curve (AUC) of intelligent analysis system	three months	AUC of the intelligent analysis system in predicting peritoneal metastasis for gastric cancer.

Secondary

Measure	Time frame	Description
The accuray of intelligent analysis system in predicting peritoneal metastasis	three months	The agreement between the prediction outcome of intelligent analysis system and the golden standard of peritoneal metastasis.

Other

Measure	Time frame	Description
The statistical significance of intelligent analysis system in risk stratification	Three years	Statistical significance (P value) of progression-free survival (PFS) in gastric cancer patients between high-risk and low-risk group identified by the intelligent analysis system.
Progression-free survival time	Three years	The progression-free survival time in patient subgroups stratified by the intelligent analysis system.
Overall survival	Three years	The overall survival time in patient subgroups stratified by the intelligent analysis system.

Countries

China, Italy

Contacts

Primary ContactDi Dong, Ph.D

di.dong@ia.ac.cn+86 010-82618465

Backup ContactYali Zang, Ph.D

yali.zang@ia.ac.cn

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026